Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

AbbVie Second Quarter Earnings Continue Climb on Humira Sales

By Pharmaceutical Processing | July 26, 2013

AbbVie Inc. topped Wall Street expectations in its second full quarter as a standalone company due to higher sales of its best-selling drug Humira.

In January, Abbott Laboratories completed the spinoff of AbbVie, which markets the company’s branded prescription drugs, including the blockbuster anti-inflammatory drug Humira.

Second-quarter revenue rose 4.4 percent to $4.69 billion, driven mainly by Humira sales. Sales of the injectable medication increased 12.1 percent to $2.6 billion. Humira is prescribed to treat a number of inflammatory diseases, including rheumatoid arthritis, psoriasis and Crohn’s Disease.

The company reported net income of $1.07 billion, or 66 cents per share, compared with $1.27 billion, or 80 cents per share, a year earlier. The decline is attributable in part to income tax expense of $300 million, more than double from 2012.

Excluding one-time charges the company would have earned $1.7 billion, or 82 cents per share. That topped the average estimate of Wall Street analysts, who predicted 79 cents per share on revenue of $4.53 billion, according to FactSet.

Sales of the company’s cholesterol pills TriCor and Trilipex continued to fall due to the expirations of their patents. Combined sales of the drugs, which are designed to raise “good” HDL cholesterol while reducing triglycerides and “bad” LDL cholesterol, fell 66 percent to $107 million.

The company raised its full-year adjusted earnings guidance to between $3.07 and $3.13 per share, from $3.03 to $3.13 per share. Analysts polled by FactSet expect earnings of $3.12 per share.

Company shares rose 62 cents to $44.86 in morning trading. Shares are up 31 percent in the year to date.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE